Circumvent Pharmaceuticals Inc.
Portland, OR
- UEI
- Y14DQ5VD56A7
- CAGE
- 7JQB4
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 4640 SW Macadam Ave #200, Portland, OR 97239, USA
- Website
- circumventpharmaceuticals.com
- Founded
- 2017
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Bolden Therapeutics Inc. | Providence, RI | — |
| Axonis Therapeutics, Inc. | Boston, MA | — |
| Adrx, Inc. | Thousand Oaks, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Epigen Biosciences Inc. | San Diego, CA | 325199 All Other Basic Organic Chemical Manufacturing |
| Aivocode, Inc. | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Circumvent Pharmaceuticals Inc. is a company that aims to develop precision medicines for neurodegenerative diseases, starting with Batten Disease. It is focused on addressing the significant unmet need of patients with heritable forms of neurodegeneration. Circumvent Pharmaceuticals Inc. is registered in SAM.gov as a corporate entity (not tax exempt) and for-profit organization.
Circumvent Pharmaceuticals Inc. has received several federal grant awards from agencies like the National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), and National Institute of Child Health and Human Development (NICHD). These awards have funded projects related to developing therapeutics for neurological disorders such as Infantile Neuronal Ceroid Lipofuscinosis (INCL or CLN1 Batten Disease), Alzheimer's Disease, and other diseases involving aberrant protein palmitoylation. The grants have supported research on developing small molecule therapies like N-tert-(butyl)hydroxylamine (NtBuHA or CIRC825) as a potential treatment for INCL, as well as developing protein palmitoylation assays to monitor treatment efficacy. Additionally, Circumvent has received funding to investigate the effects of CIRC825 on modulating the palmitoylation and activity of proteins implicated in Alzheimer's Disease pathogenesis, such as NMDAR, BACE1, APP, and Fyn kinase. The awarded projects involve conducting studies in cellular and animal models of these disorders, with the ultimate goal of advancing potential therapies towards clinical translation.
Quick answers
Is Circumvent Pharmaceuticals Inc. registered in SAM.gov?
Yes. Circumvent Pharmaceuticals Inc.'s SAM.gov registration is active through July 28, 2027.
What is Circumvent Pharmaceuticals Inc.'s most recent federal award?
Circumvent Pharmaceuticals Inc.'s most recent federal grant award is Development of n-tert-(butyl)hydroxylamine (ntbuha) as a therapeutic agent for treating infantile neuronal ceroid… (R44NS120360), from National Institute of Neurological Disorders and Stroke (NIH), on September 20, 2021.
On GovTribe
See Circumvent Pharmaceuticals Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors